Insights on the Global Anti-Aging Medicine Market

PMR is one of the leading market research companies in India. Our team of research analysts have a deep understanding and knowledge related to the latest market research techniques and use their analytical skills to curate insightful and high-quality market reports. The presented data is collected from credible primary sources including marketing heads, sales managers, product managers, industry experts, and more.

As per the report, the global Anti-Aging Medicine market reached a value of ~US$ XX in 2018 and is likely to surpass a market value of ~US$XX by the end of 2029. Further, the report reveals that the Anti-Aging Medicine market is set to grow at a CAGR of ~XX% during the forecast period (2019-2029)

Request Sample Report @ https://www.persistencemarketresearch.co/samples/26233

Critical doubts related to the Anti-Aging Medicine market addressed in the report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/26233

Segmentation of the Anti-Aging Medicine market

The report bifurcates the Anti-Aging Medicine market into different segments to provide a clear understanding of the various aspects of the market.

Regional Outlook

The regional outlook section of the report includes vital data such as the current trends, regulatory framework, The Anti-Aging Medicine market study offers critical data including, the sales volume, sales growth, and pricing analysis of the different products in the Anti-Aging Medicine market.

key players in the region.

Some of the players operating in the global anti-aging medicine market are Pfizer, Evolution GmbH, Himalaya Global Holdings Ltd., Cipla Limited, Mylan Laboratories, Novartis, Merck Group, Vitabiotics, William Ransom & Son Holdings Plc, Uni-Vite Healthcare and Health Made Easy Limited amongst others.

The report covers exhaustive analysis on:

Regional Analysis:

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/26233

Important insights present in the report:

See the original post:

High Demand for Anti-Aging Medicine from the Millennial Population to Foster the Growth of the Anti-Aging Medicine Market between 2018 2026 - 3rd...

Global Pulmonary Arterial Hypertension (Pah) Medicine Market Forecast(2020-2027) Research Report presents a comprehensive outline of Pulmonary Arterial Hypertension (Pah) Medicine industry states as well as Product Specification, Technology Development, and Key manufacturers. This study presents an in-depth analysis of market including Pulmonary Arterial Hypertension (Pah) Medicine Market share, CAGR status, market demand, and up to the present market trends with key market segments.

The Pulmonary Arterial Hypertension (Pah) Medicine Market report explores various features such as product scope, product market by application and by region, the market size for the precise product Type, sales and revenue by region forecast the Market size for various segments. The report provides detailed data concerning the most important factors (Strengths, Weaknesses, Opportunities, and Threats)of the Pulmonary Arterial Hypertension (Pah) Medicine market. The SWOT analysis gives a clear idea about the internal strengths and weaknesses, as well as its external opportunities and threats to the Pulmonary Arterial Hypertension (Pah) Medicine Market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#request_sample

Following analysis are covered in this research including, SWOT analysis, Porters Five Forces analysis, qualitative and quantitative analysis, opportunity analysis, manufacturing cost analysis, and PESTLE analysis to give a complete understanding of the global Pulmonary Arterial Hypertension (Pah) Medicine market

Prominent players operating in the Global Pulmonary Arterial Hypertension (Pah) Medicine Market are:

Bayer HealthCareActelion PharmaceuticalsPfizerGlaxoSmithKlineArena PharmaceuticalsGilead SciencesUnited Therapeutics Corporation

The Type Coverage in the Market are:

Endothelin Receptor Antagonists (ERA)Prostacyclin And Prostacyclin AnalogsPhosphodiesterase 5 (PDE-5)

Market Segment by Applications, covers:

Secondary Pulmonary Hypertension (SPH)Primary Pulmonary Hypertension (PPH)

If you have any questions or need any customization in the report, Do Inquiry Here: https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#inquiry_before_buying

Regional Analysis:

This section of this report includes region-wise and country-wise market size(in terms of Value and Volume) outlook and for the forecast period 2020 to 2027. The following are the top regions that consider this research.

Desirable feature Of The Pulmonary Arterial Hypertension (Pah) Medicine Industry Report:

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/66013

Major Highlights Pulmonary Arterial Hypertension (Pah) Medicine Market Reports:

Executive Summary

Manufacturing Cost Structure Analysis

Key Figures of Major Manufacturers

Pulmonary Arterial Hypertension (Pah) Medicine Production and Capacity Analysis

Pulmonary Arterial Hypertension (Pah) Medicine Revenue Analysis

Pulmonary Arterial Hypertension (Pah) Medicine Price Analysis

View the Detailed [emailprotected] https://www.reportspedia.com/report/-life-sciences/2015-2027-global-pulmonary-arterial-hypertension-(pah)-medicine-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/66013#table_of_contents

See more here:

Global Pulmonary Arterial Hypertension (Pah) Medicine Market Trend Shows a Speedy Growth by 2027 According to Reportspedia Research - 3rd Watch News

LOS ANGELES, United States: QY Research has recently published a report, titled Global Spinal Muscular Atrophy Medicine Market Research Report 2020. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Spinal Muscular Atrophy Medicine market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Spinal Muscular Atrophy Medicine market include: , Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1984794/global-spinal-muscular-atrophy-medicine-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Spinal Muscular Atrophy Medicine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Spinal Muscular Atrophy Medicine Market Segment By Type:

LMI-070ND-602NT-1654NusinersenNXD-30001Others

Global Spinal Muscular Atrophy Medicine Market Segment By Application:

HospitalClinicOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Spinal Muscular Atrophy Medicine market.

Key companies operating in the global Spinal Muscular Atrophy Medicine market include , Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS, Ionis Pharmaceuticals, Inc., Longevity Biotech, Inc, Neurodyn Inc., Neurotune AG, Novartis AG, Sarepta Therapeutics, Inc., Voyager Therapeutics, Inc., Vybion, Inc., WAVE Life Sciences Ltd.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1984794/global-spinal-muscular-atrophy-medicine-market

TOC

1 Spinal Muscular Atrophy Medicine Market Overview1.1 Product Overview and Scope of Spinal Muscular Atrophy Medicine1.2 Spinal Muscular Atrophy Medicine Segment by Type1.2.1 Global Spinal Muscular Atrophy Medicine Sales Growth Rate Comparison by Type (2021-2026)1.2.2 LMI-0701.2.3 ND-6021.2.4 NT-16541.2.5 Nusinersen1.2.6 NXD-300011.2.7 Others1.3 Spinal Muscular Atrophy Medicine Segment by Application1.3.1 Spinal Muscular Atrophy Medicine Sales Comparison by Application: 2020 VS 20261.3.2 Hospital1.3.3 Clinic1.3.4 Others1.4 Global Spinal Muscular Atrophy Medicine Market Size Estimates and Forecasts1.4.1 Global Spinal Muscular Atrophy Medicine Revenue 2015-20261.4.2 Global Spinal Muscular Atrophy Medicine Sales 2015-20261.4.3 Spinal Muscular Atrophy Medicine Market Size by Region: 2020 Versus 20261.5 Spinal Muscular Atrophy Medicine Industry1.6 Spinal Muscular Atrophy Medicine Market Trends 2 Global Spinal Muscular Atrophy Medicine Market Competition by Manufacturers2.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers (2015-2020)2.2 Global Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2015-2020)2.3 Global Spinal Muscular Atrophy Medicine Average Price by Manufacturers (2015-2020)2.4 Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Sites, Area Served, Product Type2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.6 Manufacturers Mergers & Acquisitions, Expansion Plans2.7 Primary Interviews with Key Spinal Muscular Atrophy Medicine Players (Opinion Leaders) 3 Spinal Muscular Atrophy Medicine Retrospective Market Scenario by Region3.1 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Sales by Region: 2015-20203.2 Global Spinal Muscular Atrophy Medicine Retrospective Market Scenario in Revenue by Region: 2015-20203.3 North America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.3.1 North America Spinal Muscular Atrophy Medicine Sales by Country3.3.2 North America Spinal Muscular Atrophy Medicine Sales by Country3.3.3 U.S.3.3.4 Canada3.4 Europe Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.4.1 Europe Spinal Muscular Atrophy Medicine Sales by Country3.4.2 Europe Spinal Muscular Atrophy Medicine Sales by Country3.4.3 Germany3.4.4 France3.4.5 U.K.3.4.6 Italy3.4.7 Russia3.5 Asia Pacific Spinal Muscular Atrophy Medicine Market Facts & Figures by Region3.5.1 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region3.5.2 Asia Pacific Spinal Muscular Atrophy Medicine Sales by Region3.5.3 China3.5.4 Japan3.5.5 South Korea3.5.6 India3.5.7 Australia3.5.8 Taiwan3.5.9 Indonesia3.5.10 Thailand3.5.11 Malaysia3.5.12 Philippines3.5.13 Vietnam3.6 Latin America Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.6.1 Latin America Spinal Muscular Atrophy Medicine Sales by Country3.6.2 Latin America Spinal Muscular Atrophy Medicine Sales by Country3.6.3 Mexico3.6.3 Brazil3.6.3 Argentina3.7 Middle East and Africa Spinal Muscular Atrophy Medicine Market Facts & Figures by Country3.7.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country3.7.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales by Country3.7.3 Turkey3.7.4 Saudi Arabia3.7.5 U.A.E 4 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Type4.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type (2015-2020)4.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type (2015-2020)4.3 Global Spinal Muscular Atrophy Medicine Price Market Share by Type (2015-2020)4.4 Global Spinal Muscular Atrophy Medicine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Global Spinal Muscular Atrophy Medicine Historic Market Analysis by Application5.1 Global Spinal Muscular Atrophy Medicine Sales Market Share by Application (2015-2020)5.2 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Application (2015-2020)5.3 Global Spinal Muscular Atrophy Medicine Price by Application (2015-2020) 6 Company Profiles and Key Figures in Spinal Muscular Atrophy Medicine Business6.1 Astellas Pharma Inc.6.1.1 Corporation Information6.1.2 Astellas Pharma Inc. Description, Business Overview and Total Revenue6.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.1.4 Astellas Pharma Inc. Products Offered6.1.5 Astellas Pharma Inc. Recent Development6.2 AveXis, Inc.6.2.1 AveXis, Inc. Corporation Information6.2.2 AveXis, Inc. Description, Business Overview and Total Revenue6.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.2.4 AveXis, Inc. Products Offered6.2.5 AveXis, Inc. Recent Development6.3 Bioblast Pharma Ltd.6.3.1 Bioblast Pharma Ltd. Corporation Information6.3.2 Bioblast Pharma Ltd. Description, Business Overview and Total Revenue6.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.3.4 Bioblast Pharma Ltd. Products Offered6.3.5 Bioblast Pharma Ltd. Recent Development6.4 Cytokinetics, Inc. 246.4.1 Cytokinetics, Inc. 24 Corporation Information6.4.2 Cytokinetics, Inc. 24 Description, Business Overview and Total Revenue6.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.4.4 Cytokinetics, Inc. 24 Products Offered6.4.5 Cytokinetics, Inc. 24 Recent Development6.5 F. Hoffmann-La Roche Ltd.6.5.1 F. Hoffmann-La Roche Ltd. Corporation Information6.5.2 F. Hoffmann-La Roche Ltd. Description, Business Overview and Total Revenue6.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.5.4 F. Hoffmann-La Roche Ltd. Products Offered6.5.5 F. Hoffmann-La Roche Ltd. Recent Development6.6 Genethon6.6.1 Genethon Corporation Information6.6.2 Genethon Description, Business Overview and Total Revenue6.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.6.4 Genethon Products Offered6.6.5 Genethon Recent Development6.7 Genzyme Corporation6.6.1 Genzyme Corporation Corporation Information6.6.2 Genzyme Corporation Description, Business Overview and Total Revenue6.6.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.4.4 Genzyme Corporation Products Offered6.7.5 Genzyme Corporation Recent Development6.8 GMP-Orphan SAS6.8.1 GMP-Orphan SAS Corporation Information6.8.2 GMP-Orphan SAS Description, Business Overview and Total Revenue6.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.8.4 GMP-Orphan SAS Products Offered6.8.5 GMP-Orphan SAS Recent Development6.9 Ionis Pharmaceuticals, Inc.6.9.1 Ionis Pharmaceuticals, Inc. Corporation Information6.9.2 Ionis Pharmaceuticals, Inc. Description, Business Overview and Total Revenue6.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.9.4 Ionis Pharmaceuticals, Inc. Products Offered6.9.5 Ionis Pharmaceuticals, Inc. Recent Development6.10 Longevity Biotech, Inc6.10.1 Longevity Biotech, Inc Corporation Information6.10.2 Longevity Biotech, Inc Description, Business Overview and Total Revenue6.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.10.4 Longevity Biotech, Inc Products Offered6.10.5 Longevity Biotech, Inc Recent Development6.11 Neurodyn Inc.6.11.1 Neurodyn Inc. Corporation Information6.11.2 Neurodyn Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.11.4 Neurodyn Inc. Products Offered6.11.5 Neurodyn Inc. Recent Development6.12 Neurotune AG6.12.1 Neurotune AG Corporation Information6.12.2 Neurotune AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.12.4 Neurotune AG Products Offered6.12.5 Neurotune AG Recent Development6.13 Novartis AG6.13.1 Novartis AG Corporation Information6.13.2 Novartis AG Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.13.4 Novartis AG Products Offered6.13.5 Novartis AG Recent Development6.14 Sarepta Therapeutics, Inc.6.14.1 Sarepta Therapeutics, Inc. Corporation Information6.14.2 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.14.4 Sarepta Therapeutics, Inc. Products Offered6.14.5 Sarepta Therapeutics, Inc. Recent Development6.15 Voyager Therapeutics, Inc.6.15.1 Voyager Therapeutics, Inc. Corporation Information6.15.2 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.15.4 Voyager Therapeutics, Inc. Products Offered6.15.5 Voyager Therapeutics, Inc. Recent Development6.16 Vybion, Inc.6.16.1 Vybion, Inc. Corporation Information6.16.2 Vybion, Inc. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.16.4 Vybion, Inc. Products Offered6.16.5 Vybion, Inc. Recent Development6.17 WAVE Life Sciences Ltd.6.17.1 WAVE Life Sciences Ltd. Corporation Information6.17.2 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Description, Business Overview and Total Revenue6.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2015-2020)6.17.4 WAVE Life Sciences Ltd. Products Offered6.17.5 WAVE Life Sciences Ltd. Recent Development 7 Spinal Muscular Atrophy Medicine Manufacturing Cost Analysis7.1 Spinal Muscular Atrophy Medicine Key Raw Materials Analysis7.1.1 Key Raw Materials7.1.2 Key Raw Materials Price Trend7.1.3 Key Suppliers of Raw Materials7.2 Proportion of Manufacturing Cost Structure7.3 Manufacturing Process Analysis of Spinal Muscular Atrophy Medicine7.4 Spinal Muscular Atrophy Medicine Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers8.1 Marketing Channel8.2 Spinal Muscular Atrophy Medicine Distributors List8.3 Spinal Muscular Atrophy Medicine Customers 9 Market Dynamics9.1 Market Trends9.2 Opportunities and Drivers9.3 Challenges9.4 Porters Five Forces Analysis 10 Global Market Forecast10.1 Global Spinal Muscular Atrophy Medicine Market Estimates and Projections by Type10.1.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Type (2021-2026)10.1.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Type (2021-2026)10.2 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Application10.2.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Application (2021-2026)10.2.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Application (2021-2026)10.3 Spinal Muscular Atrophy Medicine Market Estimates and Projections by Region10.3.1 Global Forecasted Sales of Spinal Muscular Atrophy Medicine by Region (2021-2026)10.3.2 Global Forecasted Revenue of Spinal Muscular Atrophy Medicine by Region (2021-2026)10.4 North America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.5 Europe Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.6 Asia Pacific Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.7 Latin America Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026)10.8 Middle East and Africa Spinal Muscular Atrophy Medicine Estimates and Projections (2021-2026) 11 Research Finding and Conclusion 12 Methodology and Data Source12.1 Methodology/Research Approach12.1.1 Research Programs/Design12.1.2 Market Size Estimation12.1.3 Market Breakdown and Data Triangulation12.2 Data Source12.2.1 Secondary Sources12.2.2 Primary Sources12.3 Author List12.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Visit link:

New Trend: Spinal Muscular Atrophy Medicine Market key drive and Regional Share, Trends, Competitor Analysis to 2026| Astellas Pharma Inc., AveXis,...

More than 250 medical professionals have joined an Australian doctor in his campaign to draw attention to the persecution of the Baha'i religious minority in Iran.

Joobin Hooshmand, an ophthalmology registrar working with NSW Health, launched an open letter this week amid fears the coronavirus crisis in the country would impact Baha'i inmates being held in overcrowded Iranian prisons.

The open letter, being circulated via Google Form, calls for the release of "all those who have been imprisoned due to their faith".At least 77 Baha'is have been arrested across eight Iranian provinces over recent weeks, it reads.

Doctors, dentists, nurses, optometrists, paramedics, physiotherapists, pharmacists, chiropractors, and psychologists are among those who have signed onto the letter, many of them Baha'is.

"As medical practitioners, we've seen first hand the effects of COVID on our patients," Dr Hooshmand said. "And there's a government that is putting people into harm, so I felt like this is something that's going to resonate with my fellow medical practitioners."

Dr Hooshmand, who is Baha'i, arrived in Australia as a refugee when he was 18 years old after deciding to leave Iran as the government does not permit members of the religious minority to study at university.

"For the past 40 years, none of the Baha'i children in Iran has been able to progress beyond high school, and I was one of them," he said."I want to bring international media attention to the plight of the Baha'is in Iran."

According to the United Nations, there are an estimated 350,000 Baha'is in Iran, making them the country's largest non-Muslim religious minority.

In a 2019 report, UNSpecial Rapporteur to Iran Javaid Rehman said adherents of the religion had suffered the "most egregious forms of repression, persecution, and victimisation".

Since the 1979 Iranian revolution, more than 200 Baha'is - regarded as "unprotected infidels" by Iranian authorities - have been executed "solely on the basis of their religious beliefs", the report continues.

The Middle Eastern country has been one of the hardest hit during the coronavirus pandemic. More than 279,000 cases and 14,600 deaths have been reported in Iran as of midday on Wednesday, according to the John Hopkins University tally.

Iran's leaders have estimated that up to 25 million people have been infected.

"This pandemic has made evident our interconnectedness as one humanity sharing a common home, where an outbreak of disease-causing pain and suffering in one part of the planet has implications for us all," the letter continued.

"At a time when every government should be focusing on protecting all its citizens, these Bahais, whose lives and livelihoods are under great strain, are being targeted solely due to their faith."

Originally posted here:

An Australian doctor who wasn't allowed to study medicine in Iran is drawing attention to the plight of Baha'is - SBS News

LOS ANGELES (CBSLA) The health care field has become more important than ever in the wake of the coronavirus pandemic, and one hospital group is looking to fill hundreds of positions across the Southland.

We have over 700 positions open here in our organization spanning from Orange County, Greater Los Angeles, all the way up to Palmdale, Glendale, Lisa Joins, Keck Medicine of USC human resources executive director, said.

Joins said Keck was not only looking to hire for its Southern California medical offices, but also at its three hospitals Keck Hospital, Norris Hospital and Verdugo Hills Hospital which are in need of people to fill a variety of roles.

Administrative-level positions, nursing positions, she said. We have LVN roles, IT, billing, finance, the whole gamut of positions that would be available in any industry, we have here at Keck Medicine of USC.

Those interested in entry-level positions will need at least a high school diploma or a GED, and the starting pay is $15 per hour. Among the perks of working for KECK USC is that those who get into USC could potentially go to school for free, Joins said.

We look for people who have energy, people who want to make a difference, she said. Were a great place to work, and we welcome everyone who would love to apply.

More information about careers at Keck Medicine of USC can be found online.

Go here to see the original:

Keck Medicine Of USC Looking To Fill More Than 700 Positions - CBS Los Angeles

SOUTH SAN FRANCISCO, Calif., July 21, 2020 /PRNewswire/ --Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic, non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance, today announced the publication of data in the journal Cell Reports Medicine from the Phase 1 clinical trial of efruxifermin (EFX, formerly AKR-001), a fibroblast growth factor 21 (FGF21) analog, demonstrating its potential to modulate biomarkers associated with metabolic diseases, including NASH.

In the article entitled, "AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients," researchers found that EFX demonstrated a sufficiently prolonged half-life of 3-3.5 days to support weekly dosing. In addition, with a variation in systemic concentration of only 2-fold when dosed weekly, treatment with EFX delivered larger and more consistent improvements in markers of insulin sensitivity and lipid metabolism than previously reported for FGF21 analogs, and it was reported to be generally well tolerated. Weekly administration of 70mg demonstrated larger metabolic effects than dosing every other week with 140mg, even though exposure to EFX was comparable.

"Efruxifermin is the first FGF21 analog to demonstrate a pharmacokinetic profile that would enable sustained, balanced agonism across all of FGF21's receptors with once weekly dosing," said Tim Rolph, D.Phil., chief scientific officer and co-founder of Akero, and senior author of the manuscript.

Andrew Cheng, M.D., Ph.D., president and CEO of Akero, added, "The data reported in this study provided the rationale for evaluating the efficacy and safety of EFX in NASH patients in our Phase 2a BALANCED study, which met all endpoints. Our recent readouts of liver fat reductions and improvements in histological measures showed the largest reductions in liver fat and improvements in liver histology reported to date and confirm the promising clinical profile of EFX."

In patients dosed weekly with 70mg EFX in the Phase 1 study, treatment was associated with an increase in insulin sensitivity as demonstrated by reductions in HOMA-IR. This enhancement of insulin sensivity by EFX was replicated in NASH subjects and associated with better glycemic control, as recently disclosed for the BALANCED study. Treatment with EFX in the Phase 1 study was associated with amelioration of dyslipidemia, prevalent among type 2 diabetes and NASH patients, who are susceptible to cardiovascular disease. An improved lipoprotein profile was also evident with EFX treatment in the BALANCED study.

About NASHNASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) and is estimated to affect 17 million Americans. NASH is closely linked to the obesity and diabetes epidemics seen around the world. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. NASH is a leading cause of liver transplants in the US and Europe.

About EfruxiferminEfruxifermin (EFX), formerly known as AKR-001, is Akero's lead product candidate for NASH, engineered to mimic the biological activity of native FGF21. EFX is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipoproteins. This holistic approach offers the potential to address the complex, multi-system disease state of NASH, including improvements in lipoprotein risk factors linked to cardiovascular disease the leading cause of death in NASH patients. EFX offers convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date.

AboutAkero TherapeuticsAkero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemicby developing pioneering medicines designed torestore metabolic balance to improve overall health. The company's lead product candidate, efruxifermin (formerly AKR-001), has been evaluated in 80 patients with F1-F3 fibrosis in the main portion of the BALANCED study, and Akero is currently conducting cohort C of the study in non-decompensated F4 NASH patients. Akero Therapeutics is headquartered in South San Francisco, CA. For more information, please visit http://www.akerotx.com.

Forward Looking StatementsStatements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Akero's guidance regarding its business plans and objectives for EFX, including the therapeutic potential and clinical benefits thereof, as well as the dosing, safety and tolerability of EFX; Akero's Phase 2a BALANCED clinical trial, including its initial primary efficacy results and the top-line safety/tolerability, laboratory measures and paired biopsy results; and the potential impact of COVID-19 on strategy, future operations and clinical trials.

Any forward-looking statements in this statement are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the impact of public health epidemics affecting countries or regions in which we have operations or do business, such as COVID-19, including potential negative impacts on Akero's employees, manufacturers, supply chain and production as well as on global economies and financial markets; the company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States; and risks related to the competitive landscape. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Akero's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the company's 2019 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) and quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Akero's other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Akero Therapeutics, Inc.

Home

See the original post:

Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate - PRNewswire

When the academic year begins at Tufts School of Dental Medicine at the end of July, first- and second-year students will be attending all their classes remotely, another accommodation to the realities of COVID-19. Faculty and administrators say the experiences of last springwhen TUSDM, like all Tufts schools, was abruptly launched into fulltime online educationhave offered valuable lessons in creating curricula and finding unconventional ways to connect virtually.

The transition to online learning has forced us to be creative and innovative in ways that we might not have imagined before, said Ellen Patterson, assistant professor of comprehensive care. The undiscovered silver lining, she said, was realizing how previously existing online tools could be stretched. Im always looking for ways to be interactive, and yet, I hadnt taken the time to really use some of these tools until I was forced to.

For Patterson, that meant taking advantage of the Zoom breakout rooms feature for her interprofessional education course and reconfiguring the final project for the year-long Introduction to the Dental Patient. For Rocio Saavedra, assistant professor of pediatric dentistry, it meant creating a roster of virtual child patients, complete with case histories, intraoral photographs, and digital X-rays, for students to diagnose.

It is expected the D23 and D24 classes will come back to One Kneeland Street for the winter 2021 semester starting in January, for the preclinical, hands-on work that cant be replicated online. Third- and fourth-year students, whose curriculum is heavily grounded in patient care, will be following their regular routine of simulated and clinical rotations this fall.

Rising to the challenge of this unusual moment has, in fact, energized faculty and students, said Aruna Ramesh, Associate Dean for Academic Affairs. What Ive found is that the faculty are very enthusiastic with the live Zoom lectures as they see more students attending these than the previous classroom lectures in several courses; they feel more connected to students, she said.

For someone so nave about technology, [the quick transition] freaked me out, admitted veteran professor Kanchan Ganda. But, I said to myself, you need to buckle up and do this. Before long, she was recording lectures for her multiple courses, having students present cases online, organizing online rotations, and arranging for online guest speakers. In the end, I think it was a success, she said.

Among the key takeaways from the spring that have helped shape online learning at TUSDM for this fall:

Communication: We can never overcommunicate, especially when people are virtual, said Ramesh. Irina Dragan, DG15, MSD15, DI19, director of faculty education and instructional development, emphasized that the communication also needs to be a two-way street, with input from students as important as output from instructors.

Zoom fatigue: With so many teachers becoming enthusiastic about interactive, real-time Zoom lectures, students can become overwhelmed, Ramesh said. She recommends a mix of synchronous and asynchronous lectures, mixed with smaller breakout sessions and self-paced at-home assignments.

Redesigned curriculum: Rather than carrying all the individual courses for a full semester, the first-year students will take some of their classes in sequence, and some in parallel with other courses, so that they are not juggling too many courses at the same time, throughout the term.

Dragan and her colleagues in the department of periodontics, Robert Gyurko and Camille Neste, published a paper in June in the Journal of Dental Education examining the transition at TUSDM from clinical rotations to virtual experience, available here: J Dent Educ. 2020;1-3. https://doi.org/10.1002/jdd.12298

Read the original here:

Spring's Online Transition Prepped the School of Dental Medicine for Fall - Tufts Now

Telecommunications for Tele-Medicine (PTT) and M-Health Market

DataIntelo, 21-07-2020: The research report on the Telecommunications for Tele-Medicine (PTT) and M-Health Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=96893

The Major Manufacturers Covered in this Report:MedtronicCiscoGlobalMedHuaweiAppleBoschHoneywellTeladocGEPhilipsBiotronik

The Research Study Focuses on:

By Types:HardwareSoftware

By Applications:HospitalsAmbulatory Surgical CentersHomecare SettingsLong Term Care CentersEmergency Medical Services

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=96893

The Telecommunications for Tele-Medicine (PTT) and M-Health Market Report Consists of the Following Points:

Make an Inquiry of the Telecommunications for Tele-Medicine (PTT) and M-Health Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=96893

In conclusion, the Telecommunications for Tele-Medicine (PTT) and M-Health Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Read more from the original source:

Telecommunications for Tele-Medicine (PTT) and M-Health Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Cole of Duty

More Remdesivir to come to Florida

Justin Matthews reports

TAMPA, Fla. - A shipment of 30,000 vials of remdesivir should be arriving in Florida within the next two to three days, according to Governor DeSantis, who made the announcement Sunday, July 18, 2020 at a press conference in St. Augustine, Fla.

Remdesivir is said to be very successful in treating COVID-19 patients who are fighting the virus in the intensive care unit.But with the increasing number of hospitalizations across the state, remdesivir is in high demand and hospitals have been running out of the medication.

"You also had hospitals saying this is good but what we're looking at, we're going to need more before the next shipment is scheduled to arrive," said Gov. DeSantis.

Sarasota Memorial said a previous shipment of remdesivir was only enough to help about six patients, when it had 28 still in the ICU.

This shipment should help five to 6,000 patients, according to Governor DeSantis.

More here:

Shipment of crucial medicine to treat COVID-19 patients on its way to Florida - FOX 13 Tampa Bay

The globalradiopharmaceutical and therapeutics marketshould reach $22.0 billion by 2023 from $14.1 billion in 2018 at a compound annual growth rate (CAGR) of 9.2% for the period of 2018 to 2023.

Report Scope:

The scope of this report is broad and covers type, production method, technology and applications of radiopharmaceuticals and therapeutics. By type, the market has been segmented into radiotherapy and radiopharmaceuticals. Revenue forecasts from 2017 to 2023 are provided for each segment and regional market, with estimated values derived from manufacturers total revenues.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11699

The report also includes a discussion of the major players in each region in the radiopharmaceutical and therapeutics market. Further, it explains the major drivers and regional dynamics of the global radiopharmaceutical and therapeutics market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and detailed profiles of the major vendors in this market.

Report Includes:

94 data tables and 83 additional tables An overview of the global market for radiotherapy, radiopharmaceuticals and nuclear medicines Examination of present and future strategies within the radiopharmaceuticals market, including radiopharmaceuticals for both diagnostic and therapeutic purposes Detailed description of positron emission tomography (PET) and single photon emission computed tomography (SPECT) and discussion of their applications Evaluation of market opportunities for external beam radiation therapy, internal radiation therapy and systemic radiotherapy Coverage of new products launches and product enhancement in the industry Comprehensive company profiles of major players, including Accuray Inc., Bayer Pharma AG, C. R. Bard Inc., Eli Lilly and Company, Navidea Biopharmaceuticals Inc., Siemens Healthcare, and Triad Isotopes Inc.

Summary

Population and human life expectancy are growing globally, spurring more chronic conditions and lifethreatening diseases. Obesity, a sedentary lifestyle and a lack of physical activity have further worsened the situation, leading to the increased importance of medical interventions and treatments. Despite incredible advancements in the field of medicine in the last few decades, an unmet need remains for the prevention, diagnosis and treatment of aggressive ailments such as cancer, cardiovascular diseases and central nervous system disorders.

Since the discovery of radioactivity, it has been recognized that radiation can play a role in the treatment of various diseases. Radiopharmaceuticals are a type of radioactive drug that is internally administered and intended for use in the diagnosis and treatment of diseases. Radiopharmaceuticals are now a crucial part of the healthcare industry, as they can identify various disease processes much earlier than other diagnostic tests. Applications of radiopharmaceuticals are growing significantly in the fields of cardiology, neurology, oncology and other medical specialties such as endocrinology, gastroenterology and nephrology, for both diagnostic and therapeutic purposes. Radiopharmaceuticals have also become an inevitable part of personalized medicine. Diagnostic applications account for morethan an REDACTED share of the global radiopharmaceutical market, and therapeutic applications constitutethe smaller part of the market. The market for therapeutic radiopharmaceuticals is expected to grow atsteep rate in the coming years, due to growing applications and increased demand.

Growing acceptance and utilization of nuclear medicine scans (i.e., SPECT and PET) and better availability of radiopharmaceuticals due to an increasing number of cyclotrons have significantly contributed to growth in the radiopharmaceutical industry. Innovative technological equipment leading to early and accurate diagnoses, increased awareness of radiopharmaceuticals among physicians and patients and new regulatory approvals of radiopharmaceuticals are other major driving forces for the global radiopharmaceutical market. Furthermore, increasing incidences of different types of cancers across the globe are considered a major driver behind the growth of radiopharmaceuticals and therapeutics. According to Our World in Data, approximately 19 million people had cancer in 1990; that has increased more than two-fold as of 2016, reaching 42 million worldwide. In addition, breast cancerhas been identified as the leading type of cancer, as eight million people had breast cancer in 2016. In the same year, 6.3 million, 5.7 million and 2.8 million people had colon and rectum cancer, prostate cancer and tracheal, bronchus and lung cancer, respectively. Hence, the increasing incidences of various cancers drives the need for radiopharmaceuticals and therapeutics, considering diagnostic and therapeutic areas.

The global radiopharmaceutical and therapeutics market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach more than REDACTED, an increase of REDACTED from the REDACTED in revenue in 2017.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11699

Original post:

Radiotherapy, Radiopharmaceuticals And Nuclear Medicine Market Upcoming Opportunities Size COVID-19 2023 - Cole of Duty

The Global Medicine for Osteoarthritis Pain Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=200807

The Global Medicine for Osteoarthritis Pain Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Medicine for Osteoarthritis Pain Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Medicine for Osteoarthritis Pain Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=200807

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Medicine for Osteoarthritis Pain Market as:Global Medicine for Osteoarthritis Pain Market Size & Share, by Regions

Global Medicine for Osteoarthritis Pain Market Size & Share, by ProductsOralInjectionExternal

Global Medicine for Osteoarthritis Pain Market Size & Share, ApplicationsMedical CarePersonal Care

Key PlayersPfizerJohnson & JohnsonGlaxoSmithKlineBayerEli LillyNovartisSanofiHorizon PharmaAbbottMylanDaiichi SankyoTEVAAlmatica PharmaAstellas PharmaTide PharmaceuticalIroko PharmaceuticalsHengrui PharmaceuticalAbiogen Pharma

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=200807

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Continued here:

Medicine for Osteoarthritis Pain Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | Industry Growth...

Longer life-expectancy is a cumulative effect of a healthy lifestyle and favorable environmental conditions. A trend of continuously increasing life expectancy has been a witness since a decade, primarily because of advances in medical sciences and treatment of chronic life-threatening diseases, availability of clean water and environment and other factors. This trend is projected to further show even more exponential growth graph owing to the anti-aging medicines, stem cell therapeutics, genetic screening and interventions, and high-tech biomedicines.

American Academy of Anti-Aging Medicine claimed that anti-aging medicines can add up to 10-20 years to the life expectancy of a human. Today, a combination of calorie-restricted diet, regular exercise, and anti-aging medicines are claimed to slow the process of senescence and aging. Various medicines used against the treatment of acute or chronic diseases can be considered as anti-aging medicines, however, to define anti-aging medicine market we have considered only the drugs that are directly prescribed and used for delaying the effects of aging.

To remain ahead of your competitors, request for a sample [emailprotected]https://www.persistencemarketresearch.com/samples/26233

The constantly growing demand to look young in old individuals and to remain young and youthful in young people drive the anti-aging market. The influence of aesthetics from the fashion and television industry propel the demand to retain the features and energy of younger age in old people. Additionally, the increasing number of anti-aging medicine manufacturers in the decade contribute to higher availability of the anti-aging medicine resulting in expansion of the global anti-aging medicine market. However, skeptical approach to anti-aging medicine as being an external stimulator of cell-cycles is a restraint to the expansion of anti-aging medicine market.

The global Anti-aging medicine market is segmented on basis of product type, age group, distribution channel, and region:

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/26233

The rising demand for beauty consciousness amongst people and the desire to stay young is the primary factor fueling the growth of anti-aging medicines in the market. The acclaimed benefits of the products and affordability along with regional presence compel the demand for anti-aging medicine in the global market. Hormonal replacement therapy segment in product type is expected to account maximum market share in the terms of revenue in the global anti-aging medicine market. However, antioxidant therapy segment in product type is expected to grow with the highest CAGR over the forecast years owing to the rising awareness about the plethora of benefits of antioxidants in anti-aging among the public. On the basis of the route of administration, the global anti-aging medicine market is segmented as oral, injectable and topical, out of which oral segment is expected to generate maximum revenue share over the forecast period. As per the distribution channel, the global anti-aging medicine market is segmented as hospital pharmacies, retail pharmacies, e-commerce, and drug stores. The e-commerce segment in the distribution channel is estimated to grow with the highest CAGR over the forecast time.

Regionally, the global anti-aging medicine market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America anti-aging medicine market is projected to account for the largest market share in the terms of revenue in the global anti-aging medicine market owing to the higher healthcare expenditure and presence of numerous manufacturers. Europe is expected to hold the second largest share in the global anti-aging medicine market during the forecast period because of the growing geriatric population and higher spending on healthcare products and supplements. MEA anti-aging medicine market is expected to witness sluggish growth over the forecast time owing to the limited presence of manufacturers and lower healthcare expenditure. Asia Pacific is projected to grow with the highest CAGR over the forecast years in the global anti-aging medicine market due to higher demand from end users and regional penetration of the key players in the region.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/26233

Some of the players operating in the global anti-aging medicine market are

See original here:

Growing Demand for Anti Aging Medicine Market to Significantly Increase Revenues Through 2026 - 3rd Watch News

By Medicine Hat News on July 21, 2020.

The Medicine Hat Exhibition & Stampede will be holding three drive-thru pancake breakfasts this summer.

All three events will take place on the Stampede Grounds at the Cypress Centre parking lot. All three are being held this week, running from 8-10 a.m. Wednesday, Thursday and Friday.

People will enter through the south entrance, Gate 1, then exit though Gate 2 near the Kinplex.

The pancakes are free, with 1,000 plates served each day.

Pancakes will be served with sausage, syrup and juice, with individually packaged cutlery.

Signs will be posted to direct people where to drive. There will not be anywhere offered to sit and eat the food. People are also not allowed to park and walk around to eat. No washroom areas will be made available either.

People in cars will be the only people served. Bicycles, scooters, motorcycles or any other non-enclosed forms of transportation will not be served.

Volunteers will be wearing masks and gloves during the two hours, and will be washing hands frequently.

You must be logged in to post a comment.

Visit link:

Stampede hosting trio of drive-thru pancake breakfasts this week - Medicine Hat News

Global Medicine Storage Cabinet Market Growth 2020-2025 provides a special and targeted analysis of the size, patterns, and viewpoint in the production and supply of Medicine Storage Cabinet on the globe. The report gives the analysis of key market players by throwing lights on shares of each player inside the market, growth rate, and market appeal in various regions/end users. The report discusses the market size of different segments and their growth aspects along with growth trends, varied stakeholders like investors, CEOs, traders, suppliers, global Manager, director, president, SWOT analysis i.e. strength, weakness, opportunities, and a threat to the organization and others. It covers the major market contenders, global sales growth, factors influencing and restricting the market growth, and in-depth analysis by market segmentation.

The market report mainly contains the following manufacturers: Kohler, Foremost, IKEA, Duravit, Bradley, Ketcham, Afina, Croydex, Strasser, Rangaire, American Pride,

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/126526

This report gives information related to the sales channels that companies select. Along with the dealers of these products, it also presents a summary of the top customers. The report covers minor variations in the product profile which may directly or indirectly affect the production with the appropriate description. The research report delivers detailed information about the global Medicine Storage Cabinet market introduction, market summary, global market revenue, market drivers, market restraints, market opportunities, competitive analysis, regional and country level. Additionally, technological advancements, market limitations, and challenges in forecast years from 2020 to 2025 are revealed.

The report highlights product types which are as follows: Wood, Plastic, Metal, Other,

The report highlights top applications which are as follows: Household, Commercial

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

This report will help in creating proper company decisions based on a thorough investigation of this complete Medicine Storage Cabinet competitive landscape of this industry together with in-depth profiles of their best solution providers across the globe. Market analysts have identified significant stations that are forcing the market, providing a crystal clear picture regarding future changes that may be exploited, leading to sales expansion.

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/126526/global-medicine-storage-cabinet-market-growth-2020-2025

An Outline of The Important Points of The Market Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]

Web: http://www.marketandresearch.biz

Click Here For Similar Reports:

Global Trans-2-Heptene Market 2020 Growth by Opportunities, Application, Current Trend and Forecast by 2025

Global 2-Hexanone (CAS 591-78-6) Market 2020 Segmented by Product, Application, Key Players and Regional Analysis to 2025

Global Intelligent Electronic Sphygmomanometer Market 2020 Industry Research, Business Growth, Future Investment and Emerging Trend to 2025

Global Angelic Acid Market 2020 Growth Factors, Product Overview, Segmentation and Forecast Study to 2025

Link:

Medicine Storage Cabinet Market 2020 Analytical Assessment, Key Drivers, Growth and Opportunities With COVID-19 Update - Cole of Duty

Whenever my Readers Digest magazine arrives in the mail, I immediately open it to the section called Laughter is the Best Medicine. (I subscribe to the large print edition because the jokes are so much better in large type.)

Heaven knows, we could use the best medicine right about now. And I mean, a hefty dose of it. (No person has ever died of an overdose of laughter, according to a recent article in The New York Times.)

Which is probably why our US President, Donald Trump our Comedian-in-Chief has been developing a hit comedy show (Late Night with The Donald) during this difficult period in the nations history, aided by a team of zany comedy writers including Steve Mnuchin, Mike Pence, William Barr, Mike Pompeo, and Ben Carson known among Washington DC insiders as The Riot Squad.

The President knows whats good for us. A hearty guffaw. Thats what we desperately need.

Not hydroxychloroquine. Not some poorly vetted, rushed-to-the-market pharmaceutical vaccine. Just some good old fashioned belly laughs.

On his show last week, The Donald posed in the Oval Office (aka the Boffo Barn) pretending to endorse a line of grocery store items manufactured by Goya Foods. The selection totally cracked me up: Red Kidney Beans, Adobo seasoning, White hominy, Coconut milk, and Chocolate wafers. A priceless color-blind selection if weve ever seen one. Hilarious!

Comedy on the Late Night with The Donald show, featuring his Goya Foods sketch.

The Comedian-in-Chief even talked his daughter, Ivanka, to get into the act, by having her pose in her living room with a can of Goya brand Black Beans. We rarely see Ivanka join her father in a comedy routine, but in this case, her timing and delivery were spot-on. Her choice of props Frijoles Negros really tickled my funny bone. LOL! Perfect choice, given all the laughter currently surrounding the Black Lives Matter movement.

Ivanka Trump and a can of Goya Foods Black Beans.

The joke was immediately picked up by half a dozen lesser-known American comedians Stephen Colbert, Jimmy Fallon, Seth Meyers, Trevor Noah, Jimmy Kimmel, Bill Maher several of whom totally missed The Donalds humor and assumed (mistakenly!) that the President was actually endorsing Goya products, when everyone knows the Trump family wouldnt touch a Mexican-sounding food item with a ten foot pole. (Especially not Frijoles Negros, for heavens sake.)

Late Night with The Donald has seen a crazy collection of comedy writers come and go over the past couple of seasons we can remember some of the side-splitting gags dreamed up by James Comey, John Bolton and Robert Mueller, for example but the current crop of contributors have really learned how to work with shows host, and deliver up the medicine weve all been dying for.

And speaking of dying and medicine and laughter Theres been significant research lately coming from the Centers for Disease Control finally explaining why laughter is, indeed, the best medicine. Many years ago back in the days of Bob Hope and Burns & Allen the CDC published several studies showing that aspirin was actually the best medicine. Then they got some different scientists onboard, and we were told during the heyday of comedians like Jackie Gleason and Lucille Ball that penicillin was the best. Along comes Rodney Dangerfield and Richard Prior, and the CDC changed its tune once again, and claimed that Valium was the best. (Well, it was pretty good, but maybe not the best.). Another batch of comedians arrived like Jim Carrey and Chris Rock and the CDC went through a difficult phase where they were confused about which medicine really was the best. (Too much Valium?)

Now that the President has shaken up the CDC and given the boot to some of the straight-laced yahoos who were running that show under previous administrations, were finally getting some clinical studies long-awaited! that show, definitively, that people who laugh at least twice a day have a reduced tendency to sneeze. Its long been known that a sneeze allows evil spirits to enter the body, hence the tradition of saying God bless you, whenever someone sneezes. (I even say it to myself, if no one is around.) Weve all heard the expression, Thats nothing to sneeze at which actually means, Thats nothing to laugh at thus clearly demonstrating the medical connection between sneezing and laughing.

Personally, I think the future looks wonderfully bright, now that some of our leading politicians are actually trying to look like clowns. The way things are headed, America is going to die laughing!

Read more:

READY, FIRE, AIM: Laughter is the Best Medicine - Pagosa Daily Post

The UNC School of Medicine and UNC Health have launched the Heroes Health Initiative to help support the mental health of first responders and health care workers during the COVID-19 global pandemic. The app is available through the App Store/Google Play Store in the United States, free of charge to first responders, health care workers and their organizations.

For individual health care workers, the Heroes Health app delivers short mental health self-assessments each week and displays symptom summary reports to help them better understand the state of their own mental health and changes over time. The app also provides links to immediate support and mental health resources, emphasizing free and low-cost services.

Individual health care workers who choose to participate in the initiative download the free Heroes Health app to their iOS (Apple) or Android-compatible smartphone. Each week, the app notifies workers that a brief mental health symptom assessment is available and evaluates symptoms in key domains such as sleep, stress, anxiety/worry and sadness/depression.

Immediately after completing the survey, workers can view a summary report of their symptoms and trends in their symptoms over time. The app also provides links to get immediate crisis support and other mental health resources, e.g., to improve sleep and stress. This resource list focuses on apps and services that are either free or offered at reduced costs to health care workers. The UNC-Chapel Hill website also lists mental health resources and discounts for health care workers on goods and services. Heroes Health receives no financial benefit or support from the goods or services listed.

For health care organizations that partner with the Heroes Health Initiative, the app provides a way to perform proactive worker outreach and the aggregate data necessary to identify times when/areas where more worker support is needed. Developed by the UNC Institute for Trauma Recovery, Google Cloud and volunteers across Alphabet, the universitys Heroes Health app and its launch was made possible by generous support from donors including One Mind, The Rockefeller Foundation, Bank of America, Lauder Foundation and individuals.

The initiative helps the organization support its workers in several other ways. First, anonymous group-level summaries and trends in the mental health of workers in the organization, for different types of workers and units, are shared with unit and organizational leaders each week, to help them identify times/organizational areas that would benefit from additional support.

In addition, worker feedback on organizational communication and support to workers are provided to leadership each week, providing a valuable opportunity for workers to be heard during very stressful times. Finally, workers have the option to confidentially share their individual mental health summaries with an organizational mental health worker. This provides the organizational mental health worker with the opportunity to contact workers having symptoms to offer thanks and support, a conversation, or help setting up an appointment with a mental health professional. For workers in organizations partnering with Heroes Health, the contact number for this mental health support worker is also listed in the app, so that they can contact them for confidential support and resources.

The Heroes Health Initiative was founded by UNC School of Medicine physician Dr. Samuel McLean, research vice-chair in the Department of Anesthesiology and an attending physician in the Department of Emergency Medicine. As a practicing emergency physician and COVID-19 unit worker, and a COVID-19 survivor who contracted COVID-19 and infected two of his family members, McLean understands firsthand the great challenges COVID workers face.

First responders and health care workers are facing a lot of challenges right now, McLean said. There is the personal risk of severe illness or death. Much worse, there is the anxiety and fear of infecting loved ones. This an even greater challenge for first responders or health workers who live with someone particularly vulnerable to COVID-19. Its important to give first responders and health care workers a simple, quick way to regularly check in on their mental health and immediately find resources. It is also important to provide organizations with tools that help empower them to care for each other.

From his work as an NIH-funded researcher, McLean had experience performing smartphone-based mental health assessments from thousands of trauma survivors. He contacted a close collaborator, Ron Kessler, McNeil Family Professor at Harvard Medical School, and the two of them designed a brief smartphone-based assessment, using well-validated questionnaires, to assess key domains affecting COVID-19 workers, including sleep, stress, anxiety/worry and sadness and depressive symptoms. McLean also enlisted a team of other collaborators who worked to develop the project, including:

McLean needed a technology partner to help build the app for the initiative. Alphabet the parent company of Google was a natural choice since McLeans lab was already using Google Cloud. Volunteers from Google and X (Alphabets moonshot factory) donated their time to develop the app, and Google Cloud is providing free credits from their academic research program. The Heroes Health app is built on Google Clouds implementation of the FDAs open-source MyStudies platform, allowing it to scale based on demand.

Technical support was also provided by the Boston Technology Corporation. The app, which is operated by UNC School of Medicine, is HIPAA compliant and takes advantage of Google Clouds robust security and privacy protections to protect user data.

Heroes Health is the first initiative to focus on the mental health of COVID-19 health care workers, who are under extreme pressure in this pandemic. Our volunteers were honored to be able to support such a worthwhile and important initiative, said Obi Felten, head of getting moonshots ready for contacts with the real world at X.

National mental health and brain health research nonprofit One Mind has supported McLeans ongoing trauma research work, including the AURORA study. One Mind has been helping to raise financial support for the Heroes Health Initiative.

Health care workers are working long hours in highly contagious environments, often without adequate safety equipment, and are expected to make life-saving decisions while deprioritizing their own health and the health of their families, said One Mind President Brandon Staglin. These demands place an enormous amount of stress on the physical and mental health of COVID-19 health care workers. Heroes Health will provide mental health support for our frontline caregivers and is an important demonstration of how private sector innovation is essential in our response to the pandemic.

The Rockefeller Foundation has also been a key supporter.

Health care workers show up every day to battle COVID-19 and keep us all safe. Its grueling work, said Zia Khan, senior vice president of innovation at The Rockefeller Foundation. The Rockefeller Foundation, having supported public health innovations for over 100 years, is proud to join with Google and One Mind to support the UNC School of Medicine as they launch Heroes Health to extend mental health support to these frontline workers.

As a community and country, it is important to come together to support those on the frontline taking care of our citizens with coronavirus, said Bank of America North Carolina Market President Charles Bowman. It was an easy decision to partner with The Rockefeller Foundation to fund an application of this type that will be valuable now and in the future to ensure health care workers can self-monitor and have access to the support and services they need and deserve.

The public can contribute to the ongoing support and national availability for Heroes Health by donating via its fundraising page.

See the rest here:

'Heroes Health' mental wellness app launched by School of Medicine and UNC Health - UNC Chapell Hill

By MacLean James

For The Ironton Tribune

Born into a family of doctors, Michael Basedow never really doubted that he would follow in their footsteps.

Both his parents, William and Arlene, own their own practice in Ironton. His brother and sister, Joey and Sara, are currently in their postgraduate residencies and plan to finish within the next year.

Basedow finished medical school at Lake Erie College of Osteopathic Medicine in Erie, Pennsylvania in 2017, and went on to complete his residency in Columbus at Doctors Hospital, which he finished this year. He will soon be joining his parents at their clinic as a family doctor, with an emphasis on musculoskeletal medicine and osteopathic manipulation treatment.

He sees a big need for more doctors to come to the Tri-State. It is an underserved area, and often patients will have to travel out of town to receive the care they need.

Its important for that care to be more accessible.Basedow is hoping that more young professionals and doctors will choose to return and build up their services and practices here.

But he is starting his practice during unprecedented times.The COVID-19 pandemic has brought along many challenges to the medical field. It is something he has been dealing with since March and believes will continue until at least the end of this year or longer.

The Basedow Family Clinic is currently offering telehealth services to help combat the virus, and will continue for the foreseeable future.

Basedow looks forward to serving the people he knows in the place where he grew up.

When I went to medical school I didnt exactly know what specialty I wanted to go into, he said. But spending some time with my mom and dad at their office and doing rotations with them, I got to see that patient connection they have. Its a more personal thing with a family medical doctor as opposed to specialists, who you might see only once or twice and thats it. As a family doctor you get to follow them along, sometimes from birth until death. You can get to know them pretty well. Its that personal relationship that made me gravitate toward family medicine.

See the rest here:

Ironton native returning home to practice medicine - The Tribune - Ironton Tribune

NEW YORK, NY / ACCESSWIRE / July 20, 2020 / 2020 has been a rollercoaster of a year, with Covid-19, to civil uprising across the country. You can say this year has not turned out as planned, stress is high since Quarantine began; people are turning to therapy, psychotherapy, tarot readings, mediation, prayer, anything to get their mind off of their present circumstances. There is another wave of healing that people are coming into the revelation of, it's called "Quantum Reiki". Reiki is a form of preventive care that has been trending for almost a century. It's a non- invasive medicine that allows a person to reach a profound state of wellness and healing through understanding and experiencing energy exchange. Each treatment is personalized as Reiki incorporates a balanced approach between the mind, body, spirit and the lifestyle of the person. It delivers life changing results to those who are suffering from a multitude of ailments.

If you are looking for a safe space to allow yourself to be transformed from the inside out, look no further, "Antojai Ascension Academy'' is the place you need to be. World renowned Shaman Axel is the person that will be the missing piece to your life, he is a lifelong shaman with a continuance of experience. At the age of 30, self made global entrepreneur Axel Carrasquillo, has completely changed the trajectory of his life by using these specific practices. Axel suffered a traumatic event that left him paralyzed with life with nowhere to turn, suffering from a severe case of PTSD, he wanted to find an alternative to life. None of the traditional methods worked, so Axel went on a quest to find something that will allow his consciousness to be renewed, with a new sense of freedom. With many years of searching, his thirst for life was quenched with the birth of Antojai Quantum Alchemy", Axel healed himself of PTSD within just 8 months. The results were real, he found the missing key to the quest, and now it was time to share what he learned with the world around him.

Axel began growing his network into a global phenomenon, with a 100% success rate, his new method with incorporating the collective consciousness within a person, and bridging the gap between all parts of each person helped usher in a new movement. Axel, like so many people, was suffering in silence, until he found that without treating the root we will still have the symptoms. "I founded Antojai Ascension Academy, an online global academy that teaches holistic practitioners how to modify traditional methods with Quantum consciousness theory, and advanced energy medicine. I have worked on cases like fibromyalgia, depression, and anxiety, and over 100 symptoms with great success" states Axel.

True healing of the body and soul takes a level of diving into the subconscious mind and pulling out the necessary things that need to be healed. Energy medicine has been around for thousands of years, it was developed in 1922, and not updated or modified for almost 100 years. In less than 2 years, Quantum Reiki is now being practiced in 122 out of 195 countries with over 100,000 people healed from their current state of illness.

"Applying Anojai Quantum Reiki has been the most enlightening and introspective journey I have ever pursued in my entire life! It is an ongoing process though through Quantum Reiki, I have been healed of the addictions that once plagued my daily life!! The transformation was incredible, words cannot describe. I now know my true purpose in life as I aspire to help others with Quantum Reiki, the way it has helped me. This is the way to the Source. Thank you so much!!" - Leviathan AltSpaceVR

Story continues

"I was drawn to shamanic healing last year and discovered Antojai on the web. After months of putting it off, I finally booked an appointment! I have to say that both sessions were phenomenal and powerful. I can't really describe it in words! So much grand healing and changes within me and my reality. Master Axel is a magnificent and astounding human that is so very gifted. His energy and approach to you and each session is with great care and insight. I truly appreciate him and his abilities! Always such good vibes!! Thank you so much!!!" - Jourdan Rae.

"The research and work being done by this organization and the academy are game changers for energy workers and healers. My life is never going to be the same. Thanks to Antojai, I've been realigned with my purpose." - Jacob Zufelt.

As I previously mentioned, the stresses of quarantine and Covid-19 has affected numerous kinds of people suffering from all kinds of stressors. To adjust to this new reality, Axel has embraced the power of digital tools, "I am a 30 years old global liberator that revolutionized the Reiki Holistic Medicine practice, it only took me three years to make a flourishing company. It works, the proof is in the results" Remarks Axel. Freedom awaits on the other side of your obedience, no more carrying around baggage from the past, your mind, body, and soul awaits your decision. Quantum Reiki works, allowing your subconscious to be healed with the necessary tools you will need. If you want to learn more information on Shaman Axel or more information on Antojai Ascension Academy check out the website below! Healing awaits you, the decision is yours!

To find out more about Axel's Quantum Reiki & Antojai Alchemy method, you can check out his websites antojai.us and antojai.org

CONTACT:

Paula Henderson646-736-2071phendersonnews@gmail.com

About VIP Media Group:VIP Media Group is a hybrid PR agency. Their diverse client base includes top-class entrepreneurs, public figures, influencers, and celebrities.

SOURCE: VIP Media Group

View source version on accesswire.com: https://www.accesswire.com/598145/Discover-why-Antojai-Quantum-Reiki-is-the-Future-of-Medicine

The rest is here:

Discover why Antojai Quantum Reiki is the Future of Medicine - Yahoo Finance

Parliament had already called for better traceability of research and development costs, public funding and market expenditure to make medicines more affordable in a resolution adopted in 2017.

The Commission issued guidelines to tackle shortages due to the coronavirus outbreak in April. It called on member states to lift export bans and avoid stockpiling; increase and reorganise production; ensure optimal use in hospitals by reallocating stocks; consider alternative medicines; and optimise sales in pharmacies.

The report calls on the Commission to address the issue of medicine availability and accessibility and import dependency in the upcoming EU pharmaceutical strategy.

It is expected to propose measures to help improve and accelerate access to safe and affordable medicines, support innovation in the EU pharmaceutical industry, fill market gaps (for exampled new antimicrobials) and reduce direct dependence on raw materials from non-EU countries.

MEPs are expected to vote on the report during the September plenary session.

See more here:

Medicine shortages in the EU: causes and solutions | News - EU News

Cypress County has totalled 30 cases, all recovered.

The province now has confirmed 9,587 total cases throughout the pandemic. There are currently 1,109 active cases and 8,308 Albertans have recovered. Thats an increase of 250 and 115, respectively.

There are currently 86 Albertans in hospital, an increase of 18 since Fridays update. Of the 86 in hospital, 17 are in ICU. The death toll is up three to 170.

The province completed 23,530 tests in the past 72 hours.

The South Zone has a total of 1,513 cases 1,381 recovered, an increase of 14, and 119 active, an increase of 20.

There are eight people in the zone in hospital, an increase of four. There is currently one person in ICU in the South Zone, and there have been 13 deaths.

The County of Forty Mile has eight total cases, two active cases and six recovered.

The MD of Taber has 19 total cases, seven active and 12 recovered.

Special Areas No. 2 has five active cases.

Numbers are unchanged in Brooks, where there have been 1,121 total cases 1,109 are recovered and three are active. Brooks has recorded nine deaths. The County of Newell is showing a total of 23 cases two active and 21 recovered.

The County of Warner has 47 total cases. There are now five active cases and 41 recovered. There has been one death in the county.

The City of Lethbridge has a total of 88 cases. Of those, 38 are listed as active and 50 recovered. Lethbridge County has 17 cases, 10 active cases and seven recovered.

The figures on alberta.ca are up-to-date as of end of day July 19, 2020.

Dr. Deena Hinshaw, Albertas chief medical officer of health, will provide an in-person update on Tuesday.

Go here to see the original:

Three new COVID-19 cases in Medicine Hat over the weekend - CHAT News Today